ReviewMini reviews in medicinal chemistry2026
Role of Poly (ADP-Ribose) Polymerase-1 (PARP1) and Its Inhibitors for Cancer Therapy.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPoly (ADP-ribose) polymerase (PARP) regulates transcription, replication, DNA repair, and the cell cycle. This study examines the multiple functions of PARP beyond DNA repair, including its role in immunological modulation, chemokine signaling, and the regulation of gene expression, particularly during angiogenesis and the epithelial-to-mesenchymal transition.
methodsPARP inhibitors are approved for treating malignancies by targeting vulnerabilities associated with homologous recombination (HR) insufficiency, such as that caused by BRCA1/2 malfunction. By contrasting the "double-strand break (DSB)" and "single-stranded DNA (ssDNA) gap" models of synthetic lethality, PARP inhibitors are used to treat BRCA1/2-deficient cancers. We examine how ssDNA gaps and DNA polymerase theta (POLθ) interact to influence treatment outcomes.
resultsThis review highlights that advanced research is required to bridge the gap between laboratory models and real-world scenarios, focusing on the therapeutic implications of PARP1 efficacy and resistance mechanisms in BRCA-mutated cancers. DISCUSSION: PARP inhibitors extend beyond DNA repair, with ssDNA gap-driven lethality and POLθ- mediated resistance shaping efficacy, clinical translation, and emerging roles in metastasis prevention.
conclusionWith an emphasis on specific metastatic sites and PARP-selective inhibitors, we conclude by highlighting recent clinical developments in PARP inhibitors for the prevention and treatment of distant metastases. Because of their promising results in preventing metastatic cancer, PARP inhibitors may be used more frequently in the early stages of cancer.
Indexed as
Identifiers
41582575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.